San Diego-based ACADIA Pharmaceuticals reported this morning that the U.S. Food and Drug Administration has completed its review of the firm's New Drug Application for AM-831, its small molecule for treatment of schizophrenia, and it is advancing to Phase I clinical development. ACADIA said it is working with Meiji Seika Pharma Co., Ltd on the compound. Phase I studies are used by drug companies to assess the safety of drug compounds.